Vector Core

$176,025P01FY2013HLNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Paper 28808039 Paper 28726496 Paper 28578189 Paper 28510091 Paper 28435870 Paper 27812540 Paper 27717163 Paper 26124127 Paper 25858664 Paper 25029666 Paper 24949105 Paper 24925207 Paper 24869933 Paper 24556417 Paper 24533032 Paper 24440664 Paper 24198419 Paper 23926356 Paper 23769419 Paper 23555857 Paper 23463513 Paper 23460577 Paper 23384790 Paper 22988559 Paper 22915820 Paper 22434142 Paper 22182747 Paper 22079809 Paper 21903145 Paper 21900159 Paper 21829177 Paper 21738703 Paper 21637751 Paper 21385138 Paper 21188139 Paper 20693405 Paper 20357828 Paper 19692470 Paper 19447508 Paper 19121398 Paper 18971280 Paper 18834608 Paper 18818669 Paper 18600482 Paper 18524816 Paper 18511559 Paper 18508776 Paper 18367523 Paper 17728238 Paper 17577203 Paper 17507473 Paper 17360744 Paper 17299412 Paper 17142915 Paper 17010669 Paper 16971437 Paper 16943302 Paper 16940521 Paper 16804061 Paper 16630361 Paper 16511195 Paper 16511095 Paper 16475712 Paper 16424881 Paper 16076250 Paper 15979413 Paper 15975013 Paper 15960596 Paper 15922956 Paper 15871671 Paper 15838934 Paper 15795290 Paper 15353038 Paper 15336656 Paper 15191910 Paper 15163751 Paper 15095320 Paper 15042119 Paper 14664794 Paper 12954205 Paper 12907946 Paper 12885347 Paper 12768018 Paper 12659677 Paper 12459331 Paper 12413414 Paper 12388712 Patent 9920097 Patent 9775918 Patent 9675711 Patent 9327037 Patent 9157098 Patent 8802440 Patent 8802080 Patent 8445267 Patent 8137962 Patent 7220577 Patent 7094604 Patent 5976499 Patent 12570699

Abstract

The Vector Core's primary function is to supply recombinant Adeno-associated (rAAV) viral vector stocks that are used by all subprojects of this program. In addition to supplying research grade rAAV, the Core will develop a modified scalable baculovirus production system for rAAV1 that will be used for the anticipated clinical trial described in Project 1. Finally, the Core will supply GLP grade rAAV1 for preclinical toxicology studies and primate studies for Project 1.

View original record on NIH RePORTER →